A Phase 2 interventional study of Ceralasertib and Durvalumab in Melanoma, sponsored by AstraZeneca. Active, not recruiting at 66 sites in 11 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Melanoma by AstraZeneca — 2 open to participants now, 3 under way, none of them phase 3. Melanoma · AstraZeneca.
Among the 20 studies in Melanoma by AstraZeneca, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 18th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →2 of the 20 studies in Melanoma by AstraZeneca are open now, in 4 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–130
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8 · Phase 3 1
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 85 across the 19 interventional studies, 100 across the 1 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Melanoma by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.
Biopsy sub-study: This is an open-label, non-randomised, sub-study planned in participants suitable for 3 mandatory biopsies. Serial tumour biopsies are mandated in participants recruited into the sub-study and will be taken at baseline during the screening period, during treatment with ceralasertib monotherapy and during the off-treatment period of ceralasertib monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ceralasertib on Days 1 to 7 plus durvalumab Day 8, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
Drug: Ceralasertib · Biological: Durvalumab
Participants will receive ceralasertib on Days 1 to 7, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or if a study treatment discontinuation criterion is met.
Drug: Ceralasertib
From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 1 to 7 plus durvalumab Day 8, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
Drug: Ceralasertib · Biological: Durvalumab
During Cycle 0, participants will receive ceralasertib on Days 1 to 7, followed by an off-treatment period between Days 8 to 28.
Drug: Ceralasertib
Ceralasertib (240 mg) will be administered orally twice daily.
Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
Main Study: Objective Response Rate (ORR)
ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by Response Evaluation Criteria in Solid Tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. As per planned in protocol, this outcome measure was assessed only for main study.
Time frame: Cycle 1 Day 1 (Each Cycle is 28 days) until objective disease progression or the last evaluable assessment in the absence of progression, or data cut-off (1 year 8 months)
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Center Tumor Region
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin Region
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Center Tumor Region
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7), and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin Region
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, and Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Main Study and Biopsy Study: Duration of Response (DOR)
DOR was defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Main Study and Biopsy Study: Time to Response
Time to response was defined as the time from randomization until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1. For main study blinded independent central review (BICR) data is presented, and for Biopsy sub study, investigator assessment data has been presented.
Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Main Study and Biopsy Study: Percentage Change From Baseline in Tumour Size
Percentage change from baseline in target lesion (TL) tumour size was assessed. Tumour size is the sum of the longest diameters of the target lesions. The percentage change from baseline in TL tumour size at post-baseline assessment is obtained for each participants taking the difference between the sum of the TLs at post baseline assessment and the sum of the TLs at baseline divided by the sum of the TLs at baseline times 100. Percentage change from baseline at 16 weeks for main study and 20 weeks for biopsy study in sum of target lesions has been presented. For main study, BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
Time frame: Main Study: at 16 weeks; Biopsy study: at 20 weeks
Main Study and Biopsy Study: Progression Free Survival (PFS)
PFS was defined as time from randomization until progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Main Study and Biopsy Study: Overall Survival (OS)
OS was defined as time from date of randomization until the date of death due to any cause.
Time frame: Cycle 1 Day 1 (each cycle is 28 days) until date of documented progression or data cut-off (2 years), whichever occurred first
Main Study: Plasma Concentration of Ceralasertib
Pharmacokinetic (PK) of ceralasertib alone and when in combination with durvalumab was assessed.
Time frame: From Cycle 1 to Cycle 4: Day 7 and Day 8 of each cycle (each cycle is 28 days); 90 days follow-up
Main Study and Biopsy Study: Number of Participants With Adverse Events (AEs)
The safety and tolerability of ceralasertib monotherapy and ceralasertib plus durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to a programmed death ligand 1 (PD-\[L\] 1) inhibitor was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.
Time frame: From screening (Day -28 to -1) until Safety follow-up (30 days after last dose of Ceralasertib monotherapy or 90 days after last dose of Ceralasertib+Durvalumab combination) or data cut-off (2 years), whichever occurred first
Biopsy Study: Number of Participants With Presence of PD-L1 Overtime
Pre-treatment presence and/or on-treatment and/or off-treatment changes in PD-L1 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study. The number of patients with PD-L1 expression \<1% and \>= 1% has been presented.
Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Number of Participants With Presence of pRAD50
Pre-treatment presence and/or on-treatment and/or off-treatment changes in pRAD50 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Center Tumour Region
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Cell Density in Invasive Margin Region
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Centre Tumour Region
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
Biopsy Study: Change From Baseline in Proliferation (Using Ki67+ Marker) of Carcinoma and/or Immune Cells (Including CD8+ T Cells) - Area in Invasive Margin Region
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
Time frame: Baseline, On-treatment (Cycle 0 Day 7); Off-treatment (Cycle 0 Day 15-28) (each cycle is 28 days)
This study was conducted between 11 Aug 2022 (first participants enrolled) to 12 Apr 2024 (primary completion date). The study was conducted in 11 countries.
| Milestone | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Started | 100 | 51 | 43 |
| Completed | 0 | 0 | 0 |
| Not completed | 100 | 51 | 43 |
| Withdrew: Patients ongoing in the study at data cut-off (dco) of 12-april-2024 | 19 | 3 | 6 |
| Withdrew: Subject not treated | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 9 |
| Withdrew: Withdrawal by subject | 9 | 8 | 5 |
| Withdrew: Study terminated by sponsor | 22 | 14 | 7 |
| Withdrew: Progressive disease | 1 | 2 | 0 |
| Withdrew: Patient is on survival follow up beyond dco | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 |
| Withdrew: Death | 43 | 23 | 14 |
| Withdrew: Database lock | 2 | 0 | 0 |
ORR was defined as the proportion of participants who had a complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by Response Evaluation Criteria in Solid Tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. As per planned in protocol, this outcome measure was assessed only for main study.
| Percentage of participants | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy |
|---|---|---|
| Main Study: Objective Response Rate (ORR) | 9.3 (4.3 to 16.9) | 5.8 (1.2 to 15.9) |
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Percent change | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| On-treatment | -0.976 ± 2.920 |
| Off-treatment | -0.451 ± 1.357 |
DOR was defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
| Months | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Main Study and Biopsy Study: Duration of Response (DOR) | NA (7.5 to NA) | NA (5.6 to NA) | NA (5.8 to NA) |
Time to response was defined as the time from randomization until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1. For main study blinded independent central review (BICR) data is presented, and for Biopsy sub study, investigator assessment data has been presented.
| Months | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Main Study and Biopsy Study: Time to Response | 3.5 (1.7 to 5.6) | 3.6 (2.4 to NA) | 3.7 (2.7 to NA) |
Percentage change from baseline in target lesion (TL) tumour size was assessed. Tumour size is the sum of the longest diameters of the target lesions. The percentage change from baseline in TL tumour size at post-baseline assessment is obtained for each participants taking the difference between the sum of the TLs at post baseline assessment and the sum of the TLs at baseline divided by the sum of the TLs at baseline times 100. Percentage change from baseline at 16 weeks for main study and 20 weeks for biopsy study in sum of target lesions has been presented. For main study, BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
| Percentage change from baseline | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Main Study and Biopsy Study: Percentage Change From Baseline in Tumour Size | 15.80 ± 38.14 | 11.25 ± 33.99 | 17.93 ± 38.46 |
PFS was defined as time from randomization until progression per RECIST 1.1 or death due to any cause. For main study BICR data is presented, and for Biopsy sub study, investigator assessment data has been presented.
| Months | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Main Study and Biopsy Study: Progression Free Survival (PFS) | 2.00 (1.91 to 3.52) | 1.94 (1.91 to 3.06) | 2.83 (2.76 to 4.47) |
OS was defined as time from date of randomization until the date of death due to any cause.
| Months | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Main Study and Biopsy Study: Overall Survival (OS) | 16.00 (10.48 to NA) | 12.32 (9.46 to NA) | NA (10.18 to NA) |
Pharmacokinetic (PK) of ceralasertib alone and when in combination with durvalumab was assessed.
| Nanograms per milliliter (ng/mL) | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy |
|---|---|---|
| Cycle 1 Day 7: pre-dose | 4621 ± 68.34 | 4789 ± 52.03 |
| Cycle 1 Day 7: 1 hour post-dose | 8304 ± 44.69 | 8010 ± 53.84 |
| Cycle 1 Day 8: pre-dose | 78.10 ± 43.66 | — |
| Cycle 1 Day 8: 1 hour post-dose | 379600 ± 23.05 | — |
| Cycle 2 Day 7: pre-dose | 4487 ± 70.46 | 4101 ± 40.53 |
| Cycle 2 Day 7: 1 hour post-dose | 7735 ± 53.09 | 7984 ± 45.39 |
| Cycle 2 Day 8: pre-dose | 67170 ± 47.38 | — |
| Cycle 2 Day 8: 1 hour post-dose | 425900 ± 36.73 | — |
| Cycle 3 Day 7: pre-dose | 4269 ± 44.72 | 4045 ± 51.17 |
| Cycle 3 Day 7: 1 hour post-dose | 7072 ± 41.81 | 7799 ± 41.76 |
| Cycle 3 Day 8: pre-dose | 105100 ± 50.26 | — |
| Cycle 3 Day 8: 1 hour post-dose | 460800 ± 26.48 | — |
| Cycle 4 Day 7: pre-dose | — | NA ± NA |
| Cycle 4 Day 7: 1 hour post-dose | — | 7273 ± 33.82 |
| 90 Days Follow-up | 23830 ± 79.06 | — |
The safety and tolerability of ceralasertib monotherapy and ceralasertib plus durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to a programmed death ligand 1 (PD-\[L\] 1) inhibitor was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.
| Participants | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| Any AE | 92 | 45 | 39 |
| Any AE possibly related to treatment | 74 | 36 | 29 |
| Any AE of >= CTCAE grade 3 | 34 | 16 | 13 |
| Any AE of >= CTCAE grade 3, possibly related to treatment | 17 | 9 | 4 |
| Any SAE | 19 | 5 | 9 |
| Any SAE possibly related to treatment | 3 | 2 | 0 |
| Any SAE of >= CTCAE grade 3 | 16 | 3 | 9 |
| Any SAE of >= CTCAE grade 3, possibly related to treatment | 3 | 0 | 0 |
| Any SAE with outcome death | 0 | 0 | 1 |
| Any SAE with outcome death, possibly related to treatment | 0 | 0 | 0 |
| Any AE leading to discontinuation of treatment | 1 | 1 | 1 |
| Any AE leading to discontinuation of treatment, possibly related to treatment | 1 | 1 | 1 |
| Any AE leading to drug interruption of treatment | 8 | 3 | 8 |
| Any AE leading to dose reduction of treatment | 10 | 6 | 3 |
| Any AE leading to dose modification of treatment | 14 | 8 | 9 |
| Any SAE leading to discontinuation of treatment | 0 | 0 | 0 |
| Any SAE leading to discontinuation of treatment, possibly related to treatment | 0 | 0 | 0 |
| Any SAE leading to drug interruption of treatment | 5 | 1 | 4 |
| Any SAE leading to dose reduction of treatment | 2 | 0 | 0 |
| Any SAE leading to dose modification of treatment | 5 | 1 | 4 |
| Any AE of >= CTCAE grade 3, possibly related to Ceralasertib | 16 | 9 | 4 |
| Any AE of >= CTCAE grade 3, possibly related to Durvalumab | 5 | — | 1 |
| Any SAE possibly related to Ceralasertib | 3 | 2 | 0 |
| Any SAE possibly related to Durvalumab | 1 | — | 0 |
| Any SAE of >= CTCAE grade 3, possibly related to Ceralasertib | 3 | 0 | 0 |
| Any SAE of >= CTCAE grade 3, possibly related to Durvalumab | 1 | — | 0 |
| Any SAE with outcome death, possibly related to Ceralasertib | 0 | 0 | 0 |
| Any SAE with outcome death, possibly related to Durvalumab | 0 | — | 0 |
| Any AE leading to discontinuation of Ceralasertib | 1 | 1 | 1 |
| Any AE leading to discontinuation of Durvalumab | 0 | — | 1 |
| Any AE leading to discontinuation of Ceralasertib, possibly related to Ceralasertib | 1 | 1 | 1 |
| Any AE leading to discontinuation of Durvalumab, possibly related to Durvalumab | 0 | — | 1 |
| Any AE leading to drug interruption of Ceralasertib | 6 | 3 | 8 |
| Any AE leading to drug interruption of Durvalumab | 5 | — | 2 |
| Any AE leading to dose reduction of Ceralasertib | 10 | 6 | 3 |
| Any AE leading to dose reduction of Durvalumab | 0 | — | 0 |
| Any AE leading to dose modification of Ceralasertib | 13 | 8 | 9 |
| Any AE leading to dose modification of Durvalumab | 5 | — | 2 |
| Any SAE leading to discontinuation of Ceralasertib | 0 | 0 | 0 |
| Any SAE leading to discontinuation of Durvalumab | 0 | — | 0 |
| Any SAE leading to discontinuation of Ceralasertib, possibly related to Ceralasertib | 0 | 0 | 0 |
| Any SAE leading to discontinuation of Durvalumab, possibly related to Durvalumab | 0 | — | 0 |
| Any SAE leading to drug interruption of Ceralasertib | 4 | 1 | 4 |
| Any SAE leading to drug interruption of Durvalumab | 3 | — | 1 |
| Any SAE leading to dose reduction of Ceralasertib | 2 | 0 | 0 |
| Any SAE leading to dose reduction of Durvalumab | 0 | — | 0 |
| Any SAE leading to dose modification of Ceralasertib | 4 | 1 | 4 |
| Any SAE leading to dose modification of Durvalumab | 3 | — | 1 |
Pre-treatment presence and/or on-treatment and/or off-treatment changes in PD-L1 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study. The number of patients with PD-L1 expression \<1% and \>= 1% has been presented.
| Participants | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| Tumor Positive Membrane score: Baseline: <1% PD-L1 expression | 22 |
| Tumor Positive Membrane score: Baseline: >=1% PD-L1 expression | 8 |
| Tumor Positive Membrane score: On-treatment (Cycle 0 Day 7): <1% PD-L1 expression | 14 |
| Tumor Positive Membrane score: On-treatment (Cycle 0 Day 7): >=1% PD-L1 expression | 6 |
| Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): <1% PD-L1 expression | 17 |
| Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): >=1% PD-L1 expression | 8 |
| Tumor Positive Membrane score: Off-treatment (Cycle 0 Day 15-28): unknown | 1 |
| Tumor Area Positivity score: Baseline:<1% PD-L1 expression | 12 |
| Tumor Area Positivity score: Baseline: >=1% PD-L1 expression | 18 |
| Tumor Area Positivity score: On-treatment (Cycle 0 Day 7): <1% PD-L1 expression | 10 |
| Tumor Area Positivity score: On-treatment (Cycle 0 Day 7): >=1% PD-L1 expression | 10 |
| Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): <1% PD-L1 expression | 9 |
| Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): >=1% PD-L1 expression | 16 |
| Tumor Area Positivity score: Off-treatment (Cycle 0 Day 15-28): unknown | 1 |
Pre-treatment presence and/or on-treatment and/or off-treatment changes in pRAD50 was assessed to collect tumour tissue samples, or utilise residual samples, for the analysis of tumoural biomarkers that change following treatment with ceralasertib was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Participants | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| Baseline | 29 |
| On-treatment (Cycle 0 Day 7) | 18 |
| Off-treatment (Cycle 0 Day 15-28) | 25 |
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Change in cells per mm2 | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| CD8+ IHC: On-treatment (Cycle 0 Day 7) | -183.589 ± 740.398 |
| CD8+ IHC: Off-treatment (Cycle 0 Day 15-28) | -85.259 ± 396.091 |
| Ki67+ IHC: On-treatment (Cycle 0 Day 7) | -355.399 ± 461.152 |
| Ki67+ IHC: Off-treatment (Cycle 0 Day 15-28) | 47.656 ± 1041.627 |
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Percent change | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-area in the Invasive Margin Region | NA (-0.73 to -0.73) |
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline, on-treatment and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Change in cells per mm^2 | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| On-treatment | -183.589 ± 740.398 |
| Off-treatment | -85.259 ± 396.091 |
Changes in CD8+ T-cell infiltration of tumours induced by ceralasertib monotherapy was assessed in baseline and off-treatment tumour biopsies As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Change in cells per mm^2 | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| Biopsy Study: Change From Baseline in CD8+ T-cells Tumour Infiltration-density in the Invasive Margin Region | NA (-235.53 to -235.53) |
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Change in cells per mm2 | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| CD8+ IHC: Off-treatment (Cycle 0 Day 15-28) | NA (-235.53 to -235.53) |
| Ki67+ IHC: Off-treatment (Cycle 0 Day 15-28) | NA (194.39 to 194.39) |
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Percent change | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| CD8+ cells: On-treatment (Cycle 0 Day 7) | -0.976 ± 2.920 |
| CD8+ cells: Off-treatment (Cycle 0 Day 15-28) | -0.451 ± 1.357 |
| Ki67+ Cells: On-treatment (Cycle 0 Day 7) | -1.953 ± 2.616 |
| Ki67+ Cells: Off-treatment (Cycle 0 Day 15-28) | 0.754 ± 6.931 |
Changes in the proliferation of carcinoma and/or immune cells within tumours induced by ceralasertib monotherapy was assessed. As per planned in protocol, this outcome measure was assessed only for biopsy study.
| Percent change | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|
| CD8+ cells: Off-treatment (Cycle 0 Day 15-28) | NA (-0.73 to -0.73) |
| Ki67+ Cells: Off-treatment (Cycle 0 Day 15-28) | NA (1.08 to 1.08) |
Collected over From screening (Day -28 to -1) until Safety follow-up (30 days after last dose of Ceralasertib monotherapy or 90 days after last dose of Ceralasertib+Durvalumab combination) or data cut-off (2 years), whichever occurred first. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Ceralasertib + Durvalumab | 43/100 (43%) | 19/97 (19.6%) | 86/97 (88.7%) |
| Main Study: Ceralasertib Monotherapy | 23/51 (45.1%) | 5/52 (9.6%) | 43/52 (82.7%) |
| Biopsy Study: Ceralasertib + Durvalumab | 14/41 (34.1%) | 9/41 (22%) | 34/41 (82.9%) |
| Event | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/97 | 0/52 | 2/41 |
| AnaemiaBlood and lymphatic system disorders | 3/97 | 1/52 | 0/41 |
| SepsisInfections and infestations | 1/97 | 0/52 | 1/41 |
| Urinary tract infectionInfections and infestations | 1/97 | 0/52 | 1/41 |
| UrosepsisInfections and infestations | 0/97 | 1/52 | 1/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/97 | 0/52 | 1/41 |
| Arthritis bacterialInfections and infestations | 0/97 | 0/52 | 1/41 |
| COVID-19Infections and infestations | 0/97 | 0/52 | 1/41 |
| GastroenteritisInfections and infestations | 0/97 | 0/52 | 1/41 |
| Gastroenteritis norovirusInfections and infestations | 0/97 | 0/52 | 1/41 |
| Event | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab |
|---|---|---|---|
| NauseaGastrointestinal disorders | 50/97 | 19/52 | 20/41 |
| AnaemiaBlood and lymphatic system disorders | 35/97 | 9/52 | 15/41 |
| VomitingGastrointestinal disorders | 21/97 | 8/52 | 13/41 |
| FatigueGeneral disorders | 19/97 | 14/52 | 10/41 |
| Decreased appetiteMetabolism and nutrition disorders | 20/97 | 12/52 | 11/41 |
| DiarrhoeaGastrointestinal disorders | 11/97 | 6/52 | 11/41 |
| AstheniaGeneral disorders | 22/97 | 11/52 | 8/41 |
| ConstipationGastrointestinal disorders | 10/97 | 1/52 | 8/41 |
| PruritusSkin and subcutaneous tissue disorders | 17/97 | 5/52 | 0/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/97 | 4/52 | 7/41 |
For main study: Full analysis set (FAS) included all participants who were randomized in the study. For biopsy study: Safety analysis set included all participants who received at least 1 dose of study treatment.
| Age, Continuous(Years) | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab | Total |
|---|---|---|---|---|
| Mean | 62.9 ± 13.6 | 62.9 ± 12.6 | 61.4 ± 11.9 | 62.6 ± 13.0 |
| Sex: Female, Male(Participants) | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab | Total |
|---|---|---|---|---|
| Female | 42 | 22 | 16 | 80 |
| Male | 58 | 29 | 25 | 112 |
| Race/Ethnicity, Customized(Participants) | Main Study: Ceralasertib + Durvalumab | Main Study: Ceralasertib Monotherapy | Biopsy Study: Ceralasertib + Durvalumab | Total |
|---|---|---|---|---|
| White | 79 | 39 | 31 | 149 |
| Asian | 9 | 7 | 0 | 16 |
| Other | 2 | 1 | 0 | 3 |
| Not reported | 10 | 4 | 10 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2022 to primary completion in Apr 2024, 20 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 20 months is below that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceralasertib